Enzyme-linked immunosorbent assay (Elisa) testing market size to Increase by USD 564.97 million between 2022-2027, Technavio
01 Apr 2024
Diagnostic ReagentsVaccine
NEW YORK , April 1, 2024 /PRNewswire/ -- The Enzyme-Linked Immunosorbent Assay (ELISA) testing market is set for substantial expansion, with an estimated growth of USD 564.97 million between 2022 and 2027. This growth is attributed to various factors, including the increasing demand for frequent diagnostic testing among the aging population, the rise in toxicology testing in the food industry, and the surge in chronic diseases.
To gain access to more vendor profiles available with Technavio,
Download a PDF Sample Report
Continue Reading
Preview
Source: PRNewswire
Technavio has announced its latest market research report titled Global Enzyme-linked Immunosorbent Assay (Elisa) Testing Market 2023-2027
Key Market Drivers:
The surge in chronic diseases, such as cardiovascular diseases, cancer, chronic obstructive pulmonary disease, and type 2 diabetes, is a significant driver for the market. ELISA tests play a pivotal role not only in diagnosing these diseases but also in managing them effectively. These tests aid doctors in assessing disease severity, estimating prognosis, monitoring disease progression, and selecting appropriate therapies, thereby driving market growth.
Trends Impacting Market Growth:
Promotional activities are gaining prominence in the ELISA testing market, as companies seek to enhance product visibility and awareness. Strategies such as online resources, interactive videos, and workshops are being employed to educate both healthcare professionals and patients about the benefits of ELISA testing. This trend is expected to bolster market growth in the coming years.
Challenges Faced:
Stringent government regulations pose a challenge to market growth, particularly in terms of product commercialization. Meeting regulatory requirements, including clinical trials and approvals, can be time-consuming and costly for companies. Variations in regulations across different countries further compound these challenges, affecting product development and launch timelines.
Get a glance of this market -
Download a PDF Sample Report
Major Market Players:
Key companies driving the ELISA testing market include Abbott, Abcam plc, Agilent Technologies Inc., Amgen Inc., and others. These companies are implementing various strategies such as strategic alliances, partnerships, and product launches to strengthen their market presence.
Market Segmentation:
The vaccine development segment is expected to witness significant growth during the forecast period. ELISA testing plays a crucial role in assessing immune responses to vaccine candidates, thereby supporting vaccine development and testing processes. This segment's growth is fueled by increasing investments in vaccine research and development.
Regional Analysis:
North America dominates the global ELISA testing market, with the United States and Canada leading revenue generation. The region's growth is driven by the demand for timely and accurate diagnosis of infectious and chronic diseases, coupled with the presence of numerous pharmaceutical companies focusing on drug development.
For more insights on the market -
Download a PDF Sample Report
Market Analyst Overview:
ELISA testing's versatility in detecting antibodies, biomarkers, and infectious conditions, coupled with cost-effective technologies, is propelling market growth. Automation and advancements in multiplex proteomic array platforms are enhancing testing efficiency and precision. The market is poised for expansion, particularly in cancer diagnostics and immunoassays, driven by increasing health awareness and demand for innovative disease diagnosis tools.
Conclusion:
In conclusion, the ELISA testing market is set to experience robust growth driven by factors such as the rise in chronic diseases, increasing promotional activities, and advancements in testing technologies. However, challenges related to regulatory compliance remain significant. With key players innovating and expanding their presence, the market is poised for substantial expansion, especially in regions like North America.
To learn more about this report -
Download a PDF Sample Report
Analyst Review
Enzyme-Linked Immunosorbent Assay (ELISA) has emerged as a cornerstone technology in the realm of diagnostic testing, particularly in the field of infectious diseases, chronic illnesses, and cancer research. This robust testing method, also known as ELISA assay, utilizes monoclonal antibodies (mABs) to quantify various proteins, including serum antibody concentrations, and detect antigens within biological samples like blood or serum.
The worldwide ELISA testing market has witnessed exponential growth driven by the rising prevalence of infectious diseases such as HIV, AIDS, Lyme disease, tuberculosis, meningococcal ailments, and salmonella infections. Additionally, the increasing geriatric populace has propelled the demand for efficient ailment diagnosis tools, further boosting the market value.
Continuous technological improvements have enhanced the specificity and efficiency of ELISA tests, paving the way for innovative product offerings such as sandwich ELISA and NS1 ELISA for Zika virus detection. Moreover, advancements like multiple and portable ELISA devices have expanded the market's geographical coverage, reaching previously underserved regions.
Key players in the ELISA market, including the Native Antigen Company, have focused on strategic growth initiatives such as product approvals, geographic expansions, and technological innovations to strengthen their market stake and cater to diverse application niches. Regulatory frameworks and public awareness campaigns led by organizations like the World Health Organization (WHO) and the International Society for Infectious Diseases have further facilitated market growth by promoting health awareness and disease diagnosis.
The ELISA market's future trajectory looks promising, with a forecasted compound annual growth rate (CAGR) driven by the increasing burden of infectious diseases and the growing adoption of ELISA in cancer applications. Moreover, cost-effective technologies, automation in laboratories, and the emergence of multiplex proteomic array platforms have optimized the value chain and enhanced the cost efficiency of ELISA tests.
In conclusion, the enzyme-linked immunosorbent assay (ELISA) market presents lucrative growth opportunities fueled by technological innovations, expanding application domains, and increasing health awareness. With a focus on product advancements, market regulations, and strategic expansions, players in this space are poised to capitalize on emerging revenue pockets and contribute significantly to disease diagnosis and healthcare management globally.
To learn more about this report -
Download a PDF Sample Report
Market Overview
The global Enzyme-linked Immunosorbent Assay (ELISA) market continues to expand, driven by advancements in monoclonal antibodies (mABs) and testing methods. ELISA assays are pivotal in drug discovery, aiding in ailment diagnosis and chronic illness management, especially among the geriatric populace. These tests ensure precise protein quantification and serum antibody concentrations, crucial for virus detection and food allergen identification. With evolving ELISA technology enhancing specificity, the market witnesses heightened demand for blood and serum-based assays. As the need for accurate antigen and antibody detection surges worldwide, the ELISA market remains at the forefront, offering reliable solutions for various industries, from healthcare to research and beyond.
To learn more about this report -
Download a PDF Sample Report
Related Reports:
Chromatography Market by Technology, End-user, and Geography - Forecast and Analysis 2023-2027: The chromatography market is estimated to grow at a
CAGR of 6.82% between 2022 and 2027. The size of the market is forecast to increase by
USD 3,785.83 million. The Increasing demand for ion exchange membranes for chromatography in R&D is notably driving the market growth, although factors such as product limitations the market growth.
Forensic Technologies Market by Technique, Application, and Geography - Forecast and Analysis 2023-2027: The forensic technologies market is estimated to grow at a
CAGR of 11.89% between 2022 and 2027. The size of the market is forecast to increase by
USD 6,583.87 million. The increasing crime rate demanding better investigation methods is notably driving the market growth, although factors such as lack of technical know-how or technical professionals may impede the market growth.
Table of Contents
1 Executive Summary
2 Landscape
3 Sizing
4 Historic Size
5 Five Forces Analysis
6 Segmentations
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Vendor Landscape
11 Vendor Analysis
12 Appendix
About US
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.